ASCO 2024
May 31 - June 4, 2024 | Chicago, IL
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
ARV-766, A PROteolysis TArgeting Chimera (PROTAC) Androgen Receptor Degrader, in Metastatic Castration-Resistant Prostate Cancer: Initial Results of a Phase 1/2 StudyDP Petrylak et al.
Poster
TACTIVE-K: Phase 1b/2 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Combination With PF-07220060, a Cyclin-Dependent Kinase 4 Inhibitor, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2- Advanced Breast CancerML Telli et al.